Alpha-Methylacyl-CoA Racemase (AMACR), a Potential New Biomarker for Glioblastoma

Hyunji Lee; Minhee Kim; Seon Hwan Kim; Quangdon Tran; Gyeyeong Kong; Chaeyeong Kim; So Hee Kwon; Jisoo Park; Jin Bong Park; Sungjin Park; Jongsun Park

doi:10.3389/fonc.2020.550673

Alpha-Methylacyl-CoA Racemase (AMACR), a Potential New Biomarker for Glioblastoma

Hyunji Lee, Minhee Kim, Seon Hwan Kim, Quangdon Tran, Gyeyeong Kong, Chaeyeong Kim, So Hee Kwon, Jisoo Park, Jin Bong Park, Sungjin Park, Jongsun Park

Department of Pharmacy

Research output: Contribution to journal › Article › peer-review

5 Citations (Scopus)

Abstract

Alpha-Methylacyl-CoA racemase (AMACR), which was initially discovered as a prostate cancer marker, is critical for the chiral inversion mechanism of branched-chain fatty acids. However, the function of AMACR in brain tumors has not been investigated. In this study, AMACR appeared to be involved in glioblastoma. The protein and mRNA levels of AMACR were highly elevated in glioblastoma. Downregulation of AMACR inhibited cell proliferation. Comprehensive analysis of the public REMBRANDT GBM dataset also confirmed that the level of AMACR expression was correlated with the clinical prognosis of glioma patients. In summary, these findings indicate that AMACR expression is increased in a glioblastoma cell line and glioma patients, suggesting that AMACR might be a potential diagnostic marker and therapeutic target for cancer, including glioma.

Original language	English
Article number	550673
Journal	Frontiers in Oncology
Volume	10
DOIs	https://doi.org/10.3389/fonc.2020.550673
Publication status	Published - 2020 Oct 13

Bibliographical note

Funding Information:
This work was financially supported by a research fund from Chungnam National University (grant to JoP), by Chungnam, National University Hospital Research Fund, 2012 (S-HK), by the National Research Foundation of Korea (NRF) grant funded by the Korea Government (MEST) (NRF-2015R1A2A2A01003597, NRF-2016K1A3A1A08 953546), and by a grant of the Korea Health Technology R&D Project through the Korea Health Industry Development Institute (KHIDI), funded by the Ministry of Health & Welfare, Republic of Korea (grant number: HI18C0660).

Publisher Copyright:
© Copyright © 2020 Lee, Kim, Kim, Tran, Kong, Kim, Kwon, Park, Park, Park and Park.

All Science Journal Classification (ASJC) codes

Oncology
Cancer Research

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

10.3389/fonc.2020.550673

Cite this

@article{1b0e0b1b56c349ef9c6a0b42e6bce1b2,

title = "Alpha-Methylacyl-CoA Racemase (AMACR), a Potential New Biomarker for Glioblastoma",

abstract = "Alpha-Methylacyl-CoA racemase (AMACR), which was initially discovered as a prostate cancer marker, is critical for the chiral inversion mechanism of branched-chain fatty acids. However, the function of AMACR in brain tumors has not been investigated. In this study, AMACR appeared to be involved in glioblastoma. The protein and mRNA levels of AMACR were highly elevated in glioblastoma. Downregulation of AMACR inhibited cell proliferation. Comprehensive analysis of the public REMBRANDT GBM dataset also confirmed that the level of AMACR expression was correlated with the clinical prognosis of glioma patients. In summary, these findings indicate that AMACR expression is increased in a glioblastoma cell line and glioma patients, suggesting that AMACR might be a potential diagnostic marker and therapeutic target for cancer, including glioma.",

author = "Hyunji Lee and Minhee Kim and Kim, {Seon Hwan} and Quangdon Tran and Gyeyeong Kong and Chaeyeong Kim and Kwon, {So Hee} and Jisoo Park and Park, {Jin Bong} and Sungjin Park and Jongsun Park",

note = "Funding Information: This work was financially supported by a research fund from Chungnam National University (grant to JoP), by Chungnam, National University Hospital Research Fund, 2012 (S-HK), by the National Research Foundation of Korea (NRF) grant funded by the Korea Government (MEST) (NRF-2015R1A2A2A01003597, NRF-2016K1A3A1A08 953546), and by a grant of the Korea Health Technology R&D Project through the Korea Health Industry Development Institute (KHIDI), funded by the Ministry of Health & Welfare, Republic of Korea (grant number: HI18C0660). Publisher Copyright: {\textcopyright} Copyright {\textcopyright} 2020 Lee, Kim, Kim, Tran, Kong, Kim, Kwon, Park, Park, Park and Park.",

year = "2020",

month = oct,

day = "13",

doi = "10.3389/fonc.2020.550673",

language = "English",

volume = "10",

journal = "Frontiers in Oncology",

issn = "2234-943X",

publisher = "Frontiers Media S. A.",

}

TY - JOUR

T1 - Alpha-Methylacyl-CoA Racemase (AMACR), a Potential New Biomarker for Glioblastoma

AU - Lee, Hyunji

AU - Kim, Minhee

AU - Kim, Seon Hwan

AU - Tran, Quangdon

AU - Kong, Gyeyeong

AU - Kim, Chaeyeong

AU - Kwon, So Hee

AU - Park, Jisoo

AU - Park, Jin Bong

AU - Park, Sungjin

AU - Park, Jongsun

N1 - Funding Information: This work was financially supported by a research fund from Chungnam National University (grant to JoP), by Chungnam, National University Hospital Research Fund, 2012 (S-HK), by the National Research Foundation of Korea (NRF) grant funded by the Korea Government (MEST) (NRF-2015R1A2A2A01003597, NRF-2016K1A3A1A08 953546), and by a grant of the Korea Health Technology R&D Project through the Korea Health Industry Development Institute (KHIDI), funded by the Ministry of Health & Welfare, Republic of Korea (grant number: HI18C0660). Publisher Copyright: © Copyright © 2020 Lee, Kim, Kim, Tran, Kong, Kim, Kwon, Park, Park, Park and Park.

PY - 2020/10/13

Y1 - 2020/10/13

N2 - Alpha-Methylacyl-CoA racemase (AMACR), which was initially discovered as a prostate cancer marker, is critical for the chiral inversion mechanism of branched-chain fatty acids. However, the function of AMACR in brain tumors has not been investigated. In this study, AMACR appeared to be involved in glioblastoma. The protein and mRNA levels of AMACR were highly elevated in glioblastoma. Downregulation of AMACR inhibited cell proliferation. Comprehensive analysis of the public REMBRANDT GBM dataset also confirmed that the level of AMACR expression was correlated with the clinical prognosis of glioma patients. In summary, these findings indicate that AMACR expression is increased in a glioblastoma cell line and glioma patients, suggesting that AMACR might be a potential diagnostic marker and therapeutic target for cancer, including glioma.

AB - Alpha-Methylacyl-CoA racemase (AMACR), which was initially discovered as a prostate cancer marker, is critical for the chiral inversion mechanism of branched-chain fatty acids. However, the function of AMACR in brain tumors has not been investigated. In this study, AMACR appeared to be involved in glioblastoma. The protein and mRNA levels of AMACR were highly elevated in glioblastoma. Downregulation of AMACR inhibited cell proliferation. Comprehensive analysis of the public REMBRANDT GBM dataset also confirmed that the level of AMACR expression was correlated with the clinical prognosis of glioma patients. In summary, these findings indicate that AMACR expression is increased in a glioblastoma cell line and glioma patients, suggesting that AMACR might be a potential diagnostic marker and therapeutic target for cancer, including glioma.

UR - http://www.scopus.com/inward/record.url?scp=85094568941&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85094568941&partnerID=8YFLogxK

U2 - 10.3389/fonc.2020.550673

DO - 10.3389/fonc.2020.550673

M3 - Article

AN - SCOPUS:85094568941

SN - 2234-943X

VL - 10

JO - Frontiers in Oncology

JF - Frontiers in Oncology

M1 - 550673

ER -

Alpha-Methylacyl-CoA Racemase (AMACR), a Potential New Biomarker for Glioblastoma

Abstract

Bibliographical note

All Science Journal Classification (ASJC) codes

UN SDGs

Access to Document

Other files and links

Fingerprint

Cite this